CN109432333A - A kind of synbiotic compound preparation and preparation method thereof for helping to alleviate no solid lesion hypertension symptom - Google Patents

A kind of synbiotic compound preparation and preparation method thereof for helping to alleviate no solid lesion hypertension symptom Download PDF

Info

Publication number
CN109432333A
CN109432333A CN201811181446.3A CN201811181446A CN109432333A CN 109432333 A CN109432333 A CN 109432333A CN 201811181446 A CN201811181446 A CN 201811181446A CN 109432333 A CN109432333 A CN 109432333A
Authority
CN
China
Prior art keywords
lactobacillus
synbiotic
alleviate
preparation
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811181446.3A
Other languages
Chinese (zh)
Inventor
张军毅
李东尧
单锴
周克茹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hongzhong Baide Biotechnology Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201811181446.3A priority Critical patent/CN109432333A/en
Publication of CN109432333A publication Critical patent/CN109432333A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a kind of synbiotic compound preparations for helping to alleviate no solid lesion hypertension symptom, the formula for helping to alleviate the synbiotic compound preparation of no solid lesion hypertension symptom includes following component: bifidobacterium infantis 8%-12%, bifidobacterium longum 8%-12%, bifidobacterium breve 8%-12%, lactobacillus acidophilus 3%-6%, Lactobacillus casei 3%-6%, Lactobacillus rhamnosus 3%-6%, lactobacillus plantarum 3%-6%, lactobacillus paracasei 3%-6%, lactobacillus bulgaricus 3%-6%, streptococcus thermophilus 12%-18%, sodium acetate 0.2%-0.8%, sodium butyrate 0.4%-0.8%, oligofructose 1.2%-1.5%, lactulose 0.5%-0.9%, fructus hordei germinatus powder 0.1%-0.5%, it is de- Rouge goat milk powder 1.4%-1.8%, active hexose related compound 1.3%-1.8%, inulin 0.8%-1.4%, plantago ovata shell 0.2%-0.5%, the invention also discloses a kind of preparation methods of synbiotic compound preparation for helping to alleviate no solid lesion hypertension symptom, and the preparation method is the following steps are included: quantitatively weigh, probiotic's culture, probiotics fermention is supported, and degreasing goat milk is resuspended, and mixes glue capsule.

Description

A kind of synbiotic compound preparation for helping to alleviate no solid lesion hypertension symptom And preparation method thereof
Technical field
The present invention relates to synbiotic compound preparation preparation technical field, specially one kind helps to alleviate without solid lesion Synbiotic compound preparation of hypertension symptom and preparation method thereof.
Background technique
Hypertension refer to systemic arterial blood pressure (systolic pressure and/or diastolic pressure) increase for main feature (systolic pressure >= 140 millimetress of mercury, diastolic pressure >=90 millimetress of mercury), it can be with the function of the organs such as the heart, brain, kidney or the clinic of organic lesion Syndrome.Hypertension is the most common chronic disease and the most important risk factor of cardiovascular and cerebrovascular diseases.Hypertensive patient is often accompanied by The organ functionals such as fat and sugar metabolic disorder and the heart, brain, kidney and retina or organic change.Clinically many hypertension Patient's especially endomorphy type is often accompanied by diabetes, and diabetes are also more with hypertension.Hypertension and hyperglycemia, hyperlipidemia It is known as " three high ", referred to as " the invisible killer " of human health together, is to need one of main disease of chronic disease health management.
Hypertension symptom Producing reason is complicated, including inherent cause, spirit and environmental factor, age factor, and life is practised Used factor, drug side-effect and disease are secondary etc..Medical field it is generally believed that under genetic background, practise by unsound life at present Used is that the most common inducement occurs for hypertension in community.The symptom of hypertension varies with each individual.Early stage possible asymptomatic or symptom is not Obviously, it can be common that dizzy, headache, neck plate tight, fatigue, palpitaition etc..It only can be after tired, nervous, mood swing Blood pressure occurs to increase, and is being returned to normal after a break.Blood pressure significantly persistently increases with the prolongation of the disease course, gradually will appear each Kind symptom.It is referred to as benign hypertension at this time.The common clinical symptoms of benign hypertension have headache, dizziness, attention Power is not concentrated, failure of memory, extremity numbness, enuresis nocturna increase, palpitaition, uncomfortable in chest, out of strength etc..When blood pressure is suddenly increased to certain journey It even will appear the symptoms such as severe headache, vomiting, palpitaition, dizziness when spending, clouded in mind, twitch can occur when serious, this just belongs to In accelerated hypertension and hypertension critical illness, the damage and disease of the organs such as the serious heart, brain, kidney can mostly occur in a short time Become, such as apoplexy, heart infarction, renal failure.Symptom and the raised level of blood pressure have no consistent relationship.
Hypertension specific for the cause of disease at present mainly uses etiological treatment scheme；However to the height that the cause of disease is still not clear Blood pressure generally uses angiotensins class, and calcium channel class, beta-receptor class or diuresis class drug are subject to symptomatic treatment.But Be hypertension it is unknown due to (such as the bad life habits such as genetic predisposition and high salt diet) do not release, receive to suit the medicine to the illness The hypertensive patient for the treatment of generally requires lifelong medication, and due to the drug resistance that long-term administration will lead to, curative effect of medication can be got over It is poorer to come, and increases the financial burden of patient, reduces quality of life.
Probiotics is a kind of active microorganism beneficial to host, is to be colonized in human body intestinal canal, in reproductive system, can generate Definite health efficacy so as to improve host's microecological balance, play the active beneficial microorganism general name of beneficial effect.And it is prebiotic Member is the natural food ingredients of a kind of safety, can promote the field planting and proliferation of probiotics.In animal and clinical research, The SHR high that can alleviate even treatment high-sodium diet to some extent is used in combination in the exclusive use of a variety of probiotics and prebiotics The hypertension symptom of blood pressure rats shows extremely strong healthcare function.Part of probiotics then unambiguously belongs to the Ministry of Public Health, China The microorganism register that can be used for food formulated, safety with higher.In addition, even for general population, probiotics with Prebiotics can also play the good action for promoting intestinal health, and be applied to such as chlorella yakult in daily beverage Deng.
However, probiotics is different in the mechanism respectively functioned from the single use of prebiotics, for different individuals The difference of health-care effect can be shown due to individual difference；For this purpose, the present invention proposes that one kind helps to alleviate without solid lesion Synbiotic compound preparation of hypertension symptom and preparation method thereof.
Summary of the invention
The purpose of the present invention is to provide a kind of synbiotic compounds for helping to alleviate no solid lesion hypertension symptom Preparation and preparation method thereof, to solve the problems mentioned in the above background technology.
To achieve the above object, the invention provides the following technical scheme: one kind helps to alleviate without the high blood of solid lesion The synbiotic compound preparation of symptom is pressed, this helps to alleviate matching for the synbiotic compound preparation of no solid lesion hypertension symptom Side includes following component: bifidobacterium infantis 8%-12%, bifidobacterium longum 8%-12%, bifidobacterium breve 8%-12%, acidophilus cream bar Bacterium 3%-6%, Lactobacillus casei 3%-6%, Lactobacillus rhamnosus 3%-6%, lactobacillus plantarum 3%-6%, lactobacillus paracasei 3%-6%, Lactobacillus bulgaricus 3%-6%, streptococcus thermophilus 12%-18%, sodium acetate 0.2%-0.8%, sodium butyrate 0.4%-0.8%, oligomeric fruit Sugared 1.2%-1.5%, lactulose 0.5%-0.9%, fructus hordei germinatus powder 0.1%-0.5%, degreasing goat milk powder 1.4%-1.8%, active hexose phase Related compounds 1.3%-1.8%, inulin 0.8%-1.4%, plantago ovata shell 0.2%-0.5%.
Preferably, including bifidobacterium infantis 8%, bifidobacterium longum 8%, bifidobacterium breve 8%, lactobacillus acidophilus 3%, cheese Lactobacillus 3%, Lactobacillus rhamnosus 3%, lactobacillus plantarum 3%, lactobacillus paracasei 3%, lactobacillus bulgaricus 3%, thermophilus Bacterium 12%, sodium acetate 0.2%, sodium butyrate 0.4%, oligofructose 1.2%, lactulose 0.5%, fructus hordei germinatus powder 0.1%, degreasing goat milk powder 1.4%, active hexose related compound 1.3%, inulin 0.8%, plantago ovata shell 0.2%.
Preferably, including bifidobacterium infantis 9%, bifidobacterium longum 9%, bifidobacterium breve 9%, lactobacillus acidophilus 4%, cheese Lactobacillus 4%, Lactobacillus rhamnosus 4%, lactobacillus plantarum 4%, lactobacillus paracasei 4%, lactobacillus bulgaricus 4%, thermophilus Bacterium 13%, sodium acetate 0.3%, sodium butyrate 0.5%, oligofructose 1.3%, lactulose 0.6%, fructus hordei germinatus powder 0.2%, degreasing goat milk powder 1.5%, active hexose related compound 1.4%, inulin 0.9%, plantago ovata shell 0.3%.
Preferably, including bifidobacterium infantis 10%, bifidobacterium longum 10%, bifidobacterium breve 10%, lactobacillus acidophilus 5%, Lactobacillus casei 5%, Lactobacillus rhamnosus 5%, lactobacillus plantarum 5%, lactobacillus paracasei 5%, lactobacillus bulgaricus 5% is thermophilic Streptococcus 14%, sodium acetate 0.4%, sodium butyrate 0.6%, oligofructose 1.4%, lactulose 0.7%, fructus hordei germinatus powder 0.3%, degreasing goat milk Powder 1.6%, active hexose related compound 1.5%, inulin 1%, plantago ovata shell 0.4%.
Preferably, including bifidobacterium infantis 11%, bifidobacterium longum 11%, bifidobacterium breve 11%, lactobacillus acidophilus 6%, Lactobacillus casei 6%, Lactobacillus rhamnosus 6%, lactobacillus plantarum 6%, lactobacillus paracasei 6%, lactobacillus bulgaricus 6% is thermophilic Streptococcus 18%, sodium acetate 0.5%, sodium butyrate 0.7%, oligofructose 1.5%, lactulose 0.8%, fructus hordei germinatus powder 0.4%, degreasing goat milk Powder 1.7%, active hexose related compound 1.6%, inulin 1.1%, plantago ovata shell 0.5%.
Preferably, the bifidobacterium infantis number is 1222, and bifidobacterium longum number is CCM 7952, bifidobacterium breve Number is M-16V, and lactobacillus acidophilus number NCFM, Lactobacillus casei number is DN-114 001, and Lactobacillus rhamnosus number is LGG。
Preferably, every powder charge 0.5g of described synbiotic compound preparation, containing 10 kinds of probiotics at least total 1010CFU is living Bacterium and 9 kinds of total 0.05g of prebiotics；The number of active bifid bacteria in probiotics: living preparation of lactobacillus number: streptococcus viable count ratio is 2: 2:1；Every kind of the number of active bifid bacteria is equal；Every kind of living preparation of lactobacillus number is equal.
It is a kind of to help to alleviate the preparation of the synbiotic compound preparation of no solid lesion hypertension symptom as described above Method, the preparation method the following steps are included:
S1: quantitatively weighing, and all raw materials are weighed according to above-mentioned component；
S2: probiotic's culture, by bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, lactobacillus bulgaricus and streptococcus thermophilus are respectively put into ten Further expansion culture is carried out in culture dish；
S3: probiotics fermention is supported, and is being fermented, will fermented respectively to above-mentioned 10 kinds of probiotics using food-grade microorganisms fermentation condition Liquid is filtered using 0.22 micron membrane filter, obtains wet thallus；
S4: degreasing goat milk is resuspended, to wet thallus obtained by step 3 inside degreasing goat milk is added, it is resuspended, and using cold Freeze the dry acquisition freeze-dried vaccine powder of seasoning, is saved at -20 degrees Celsius；
S5: identification is quantitative again, and the probiotic powder after fermentation is used technology plate assay viable bacteria density, is walked for S6-1 or S6-2 Suddenly；
S6-1: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio and are made capsule by mixing glue capsule, Capsule uses enteric solubility outer wall, and protection synbiotic completely passes through stomach, into enteron aisle, guarantees probiotics viability, and -20 ~ 4 Degree Celsius storage cold chain transportation and sale；
S6-2: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio, degreasing are added by mixing solid beverage processed Solid beverage is made in goat milk powder and other auxiliary materials, and in -20 ~ 4 degrees Celsius of storage cold chain transportations and sale.
Compared with prior art, the beneficial effects of the present invention are: formula of the present invention is national regulations raw material, And the synbiotic compound preparation that the present invention prepares is highly improved, the capsule of synbiotic compound preparation capsule agent uses enteric Property outer wall, protection synbiotic completely passes through stomach, into enteron aisle, guarantees probiotics viability；Synbiotic compound preparation solid drink Material uses degreasing goat milk powder to also further improve as filler in addition to further playing the prebiotic function of goat milk convenient for eating Nutritive value, avoids the adverse reaction that dairy product may cause.This compound preparation is to no solid lesion vascular hypertension Shape has improvement result, and has obvious adjuvant treatment effect and no apparent side effect to Current treatments scheme；And system of the present invention The cost of standby synbiotic compound preparation decreases, and increases enterprise income, is suitble to promote.
Specific embodiment
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common Technical staff's every other embodiment obtained without making creative work belongs to the model that the present invention protects It encloses.
Embodiment one
The present invention provides a kind of technical solution: a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom Agent, this helps to alleviate the formula of the synbiotic compound preparation of no solid lesion hypertension symptom to include following component: including Bifidobacterium infantis 8%, bifidobacterium longum 8%, bifidobacterium breve 8%, lactobacillus acidophilus 3%, Lactobacillus casei 3%, rhamnose cream bar Bacterium 3%, lactobacillus plantarum 3%, lactobacillus paracasei 3%, lactobacillus bulgaricus 3%, streptococcus thermophilus 12%, sodium acetate 0.2%, fourth Sour sodium 0.4%, oligofructose 1.2%, lactulose 0.5%, fructus hordei germinatus powder 0.1%, degreasing goat milk powder 1.4%, active hexose related compounds Object 1.3%, inulin 0.8%, plantago ovata shell 0.2%.
Wherein, bifidobacterium infantis number is 1222, and bifidobacterium longum number is CCM 7952, and bifidobacterium breve number is M-16V, lactobacillus acidophilus number NCFM, Lactobacillus casei number are DN-114 001, and Lactobacillus rhamnosus number is LGG；This Every powder charge 0.5g of synbiotic compound preparation, containing 10 kinds of probiotics at least total 1010CFU viable bacteria and 9 kinds of total 0.05g of prebiotics； The number of active bifid bacteria in probiotics: living preparation of lactobacillus number: streptococcus viable count ratio is 2:2:1；Every kind of bifidobacteria viable bacteria Number is equal；Every kind of living preparation of lactobacillus number is equal.
It is a kind of to help to alleviate the preparation of the synbiotic compound preparation of no solid lesion hypertension symptom as described above Method, the preparation method the following steps are included:
S1: quantitatively weighing, and all raw materials are weighed according to above-mentioned component；
S2: probiotic's culture, by bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, lactobacillus bulgaricus and streptococcus thermophilus are respectively put into ten Further expansion culture is carried out in culture dish；
S3: probiotics fermention is supported, and is being fermented, will fermented respectively to above-mentioned 10 kinds of probiotics using food-grade microorganisms fermentation condition Liquid is filtered using 0.22 micron membrane filter, obtains wet thallus；
S4: degreasing goat milk is resuspended, to wet thallus obtained by step 3 inside degreasing goat milk is added, it is resuspended, and using cold Freeze the dry acquisition freeze-dried vaccine powder of seasoning, is saved at -20 degrees Celsius；
S5: identification is quantitative again, and the probiotic powder after fermentation is used technology plate assay viable bacteria density；
S6: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio and are made capsule, glue by mixing glue capsule Capsule uses enteric solubility outer wall, and protection synbiotic completely passes through stomach, into enteron aisle, guarantees probiotics viability, and at 4 degrees Celsius Store cold chain transportation and sale.
Embodiment two
The present invention provides a kind of technical solution: a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom Agent, this helps to alleviate the formula of the synbiotic compound preparation of no solid lesion hypertension symptom to include following component: including Bifidobacterium infantis 9%, bifidobacterium longum 9%, bifidobacterium breve 9%, lactobacillus acidophilus 4%, Lactobacillus casei 4%, rhamnose cream bar Bacterium 4%, lactobacillus plantarum 4%, lactobacillus paracasei 4%, lactobacillus bulgaricus 4%, streptococcus thermophilus 13%, sodium acetate 0.3%, fourth Sour sodium 0.5%, oligofructose 1.3%, lactulose 0.6%, fructus hordei germinatus powder 0.2%, degreasing goat milk powder 1.5%, active hexose related compounds Object 1.4%, inulin 0.9%, plantago ovata shell 0.3%.
Wherein, bifidobacterium infantis number is 1222, and bifidobacterium longum number is CCM 7952, and bifidobacterium breve number is M-16V, lactobacillus acidophilus number NCFM, Lactobacillus casei number are DN-114 001, and Lactobacillus rhamnosus number is LGG；This Every powder charge 0.5g of synbiotic compound preparation, containing 10 kinds of probiotics at least total 1010CFU viable bacteria and 9 kinds of total 0.05g of prebiotics； The number of active bifid bacteria in probiotics: living preparation of lactobacillus number: streptococcus viable count ratio is 2:2:1；Every kind of bifidobacteria viable bacteria Number is equal；Every kind of living preparation of lactobacillus number is equal.
It is a kind of to help to alleviate the preparation of the synbiotic compound preparation of no solid lesion hypertension symptom as described above Method, the preparation method the following steps are included:
S1: quantitatively weighing, and all raw materials are weighed according to above-mentioned component；
S2: probiotic's culture, by bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, lactobacillus bulgaricus and streptococcus thermophilus are respectively put into ten Further expansion culture is carried out in culture dish；
S3: probiotics fermention is supported, and is being fermented, will fermented respectively to above-mentioned 10 kinds of probiotics using food-grade microorganisms fermentation condition Liquid is filtered using 0.22 micron membrane filter, obtains wet thallus；
S4: degreasing goat milk is resuspended, to wet thallus obtained by step 3 inside degreasing goat milk is added, it is resuspended, and using cold Freeze the dry acquisition freeze-dried vaccine powder of seasoning, is saved at -20 degrees Celsius；
S5: identification is quantitative again, and the probiotic powder after fermentation is used technology plate assay viable bacteria density；
S6: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio and are made capsule, glue by mixing glue capsule Capsule uses enteric solubility outer wall, and protection synbiotic completely passes through stomach, into enteron aisle, guarantees probiotics viability, and Celsius -20 Degree storage cold chain transportation and sale.
Embodiment three
The present invention provides a kind of technical solution: a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom Agent, this helps to alleviate the formula of the synbiotic compound preparation of no solid lesion hypertension symptom to include following component: including Bifidobacterium infantis 10%, bifidobacterium longum 10%, bifidobacterium breve 10%, lactobacillus acidophilus 5%, Lactobacillus casei 5%, rhamnose Lactobacillus 5%, lactobacillus plantarum 5%, lactobacillus paracasei 5%, lactobacillus bulgaricus 5%, streptococcus thermophilus 14%, sodium acetate 0.4%, sodium butyrate 0.6%, oligofructose 1.4%, lactulose 0.7%, fructus hordei germinatus powder 0.3%, degreasing goat milk powder 1.6%, active hexose Related compound 1.5%, inulin 1%, plantago ovata shell 0.4%.
Wherein, bifidobacterium infantis number is 1222, and bifidobacterium longum number is CCM 7952, and bifidobacterium breve number is M-16V, lactobacillus acidophilus number NCFM, Lactobacillus casei number are DN-114 001, and Lactobacillus rhamnosus number is LGG；This Every powder charge 0.5g of synbiotic compound preparation, containing 10 kinds of probiotics at least total 1010CFU viable bacteria and 9 kinds of total 0.05g of prebiotics； The number of active bifid bacteria in probiotics: living preparation of lactobacillus number: streptococcus viable count ratio is 2:2:1；Every kind of bifidobacteria viable bacteria Number is equal；Every kind of living preparation of lactobacillus number is equal.
It is a kind of to help to alleviate the preparation of the synbiotic compound preparation of no solid lesion hypertension symptom as described above Method, the preparation method the following steps are included:
S1: quantitatively weighing, and all raw materials are weighed according to above-mentioned component；
S2: probiotic's culture, by bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, lactobacillus bulgaricus and streptococcus thermophilus are respectively put into ten Further expansion culture is carried out in culture dish；
S3: probiotics fermention is supported, and is being fermented, will fermented respectively to above-mentioned 10 kinds of probiotics using food-grade microorganisms fermentation condition Liquid is filtered using 0.22 micron membrane filter, obtains wet thallus；
S4: degreasing goat milk is resuspended, to wet thallus obtained by step 3 inside degreasing goat milk is added, it is resuspended, and using cold Freeze the dry acquisition freeze-dried vaccine powder of seasoning, is saved at -20 degrees Celsius；
S5: identification is quantitative again, and the probiotic powder after fermentation is used technology plate assay viable bacteria density；
S6: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio, degreasing sheep are added by mixing solid beverage processed Solid beverage is made in milk powder and other auxiliary materials, and in 4 degrees Celsius of storage cold chain transportations and sale.
Example IV
The present invention provides a kind of technical solution: a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom Agent, this helps to alleviate the formula of the synbiotic compound preparation of no solid lesion hypertension symptom to include following component: including Bifidobacterium infantis 11%, bifidobacterium longum 11%, bifidobacterium breve 11%, lactobacillus acidophilus 6%, Lactobacillus casei 6%, rhamnose Lactobacillus 6%, lactobacillus plantarum 6%, lactobacillus paracasei 6%, lactobacillus bulgaricus 6%, streptococcus thermophilus 18%, sodium acetate 0.5%, sodium butyrate 0.7%, oligofructose 1.5%, lactulose 0.8%, fructus hordei germinatus powder 0.4%, degreasing goat milk powder 1.7%, active hexose Related compound 1.6%, inulin 1.1%, plantago ovata shell 0.5%.
Wherein, bifidobacterium infantis number is 1222, and bifidobacterium longum number is CCM 7952, and bifidobacterium breve number is M-16V, lactobacillus acidophilus number NCFM, Lactobacillus casei number are DN-114 001, and Lactobacillus rhamnosus number is LGG；This Every powder charge 0.5g of synbiotic compound preparation, containing 10 kinds of probiotics at least total 1010CFU viable bacteria and 9 kinds of total 0.05g of prebiotics； The number of active bifid bacteria in probiotics: living preparation of lactobacillus number: streptococcus viable count ratio is 2:2:1；Every kind of bifidobacteria viable bacteria Number is equal；Every kind of living preparation of lactobacillus number is equal.
It is a kind of to help to alleviate the preparation of the synbiotic compound preparation of no solid lesion hypertension symptom as described above Method, the preparation method the following steps are included:
S1: quantitatively weighing, and all raw materials are weighed according to above-mentioned component；
S2: probiotic's culture, by bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, lactobacillus bulgaricus and streptococcus thermophilus are respectively put into ten Further expansion culture is carried out in culture dish；
S3: probiotics fermention is supported, and is being fermented, will fermented respectively to above-mentioned 10 kinds of probiotics using food-grade microorganisms fermentation condition Liquid is filtered using 0.22 micron membrane filter, obtains wet thallus；
S4: degreasing goat milk is resuspended, to wet thallus obtained by step 3 inside degreasing goat milk is added, it is resuspended, and using cold Freeze the dry acquisition freeze-dried vaccine powder of seasoning, is saved at -20 degrees Celsius；
S5: identification is quantitative again, and the probiotic powder after fermentation is used technology plate assay viable bacteria density；
S6: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio, degreasing sheep are added by mixing solid beverage processed Solid beverage is made in milk powder and other auxiliary materials, and in -20 degrees Celsius of storage cold chain transportations and sale.
By carrying out composition detection to four groups of embodiments, and one group of synbiotic compound preparation is picked from the market and is carried out Comparison, testing result are as follows:
From the experimental data of upper table it is found that the probiotics viability of second group of synbiotic compound preparation (capsule) of this programme most Height, and the synergistic function of 10 kinds of probiotics is best, the probiotics survival of the 4th group of synbiotic compound preparation (solid beverage) Property is preferable, and the synergistic function of 10 kinds of probiotics is preferable, therefore all has preferable promotional value.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding And modification, the scope of the present invention is defined by the appended.

Claims (8)

1. a kind of synbiotic compound preparation for helping to alleviate no solid lesion hypertension symptom, it is characterised in that；This is helped In alleviate the synbiotic compound preparation without solid lesion hypertension symptom formula include following component: bifidobacterium infantis 8%-12%, bifidobacterium longum 8%-12%, bifidobacterium breve 8%-12%, lactobacillus acidophilus 3%-6%, Lactobacillus casei 3%-6%, sandlwood Sugared lactobacillus 3%-6%, lactobacillus plantarum 3%-6%, lactobacillus paracasei 3%-6%, lactobacillus bulgaricus 3%-6%, thermophilus Bacterium 12%-18%, sodium acetate 0.2%-0.8%, sodium butyrate 0.4%-0.8%, oligofructose 1.2%-1.5%, lactulose 0.5%-0.9%, Fructus hordei germinatus powder 0.1%-0.5%, degreasing goat milk powder 1.4%-1.8%, active hexose related compound 1.3%-1.8%, inulin 0.8%- 1.4%, plantago ovata shell 0.2%-0.5%.
2. a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom according to claim 1 Agent, it is characterised in that: including bifidobacterium infantis 8%, bifidobacterium longum 8%, bifidobacterium breve 8%, lactobacillus acidophilus 3%, cheese Lactobacillus 3%, Lactobacillus rhamnosus 3%, lactobacillus plantarum 3%, lactobacillus paracasei 3%, lactobacillus bulgaricus 3%, thermophilus Bacterium 12%, sodium acetate 0.2%, sodium butyrate 0.4%, oligofructose 1.2%, lactulose 0.5%, fructus hordei germinatus powder 0.1%, degreasing goat milk powder 1.4%, active hexose related compound 1.3%, inulin 0.8%, plantago ovata shell 0.2%.
3. a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom according to claim 1 Agent, it is characterised in that: including bifidobacterium infantis 9%, bifidobacterium longum 9%, bifidobacterium breve 9%, lactobacillus acidophilus 4%, cheese Lactobacillus 4%, Lactobacillus rhamnosus 4%, lactobacillus plantarum 4%, lactobacillus paracasei 4%, lactobacillus bulgaricus 4%, thermophilus Bacterium 13%, sodium acetate 0.3%, sodium butyrate 0.5%, oligofructose 1.3%, lactulose 0.6%, fructus hordei germinatus powder 0.2%, degreasing goat milk powder 1.5%, active hexose related compound 1.4%, inulin 0.9%, plantago ovata shell 0.3%.
4. a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom according to claim 1 Agent, it is characterised in that: including bifidobacterium infantis 10%, bifidobacterium longum 10%, bifidobacterium breve 10%, lactobacillus acidophilus 5% done Lactobacillus paracasei 5%, Lactobacillus rhamnosus 5%, lactobacillus plantarum 5%, lactobacillus paracasei 5%, lactobacillus bulgaricus 5%, thermophilic chain Coccus 14%, sodium acetate 0.4%, sodium butyrate 0.6%, oligofructose 1.4%, lactulose 0.7%, fructus hordei germinatus powder 0.3%, degreasing goat milk powder 1.6%, active hexose related compound 1.5%, inulin 1%, plantago ovata shell 0.4%.
5. a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom according to claim 1 Agent, it is characterised in that: including bifidobacterium infantis 11%, bifidobacterium longum 11%, bifidobacterium breve 11%, lactobacillus acidophilus 6% done Lactobacillus paracasei 6%, Lactobacillus rhamnosus 6%, lactobacillus plantarum 6%, lactobacillus paracasei 6%, lactobacillus bulgaricus 6%, thermophilic chain Coccus 18%, sodium acetate 0.5%, sodium butyrate 0.7%, oligofructose 1.5%, lactulose 0.8%, fructus hordei germinatus powder 0.4%, degreasing goat milk powder 1.7%, active hexose related compound 1.6%, inulin 1.1%, plantago ovata shell 0.5%.
6. a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom according to claim 1 Agent, it is characterised in that: the bifidobacterium infantis number is 1222, and bifidobacterium longum number is CCM 7952, bifidobacterium breve Number is M-16V, and lactobacillus acidophilus number NCFM, Lactobacillus casei number is DN-114 001, and Lactobacillus rhamnosus number is LGG。
7. a kind of synbiotic compound system for helping to alleviate no solid lesion hypertension symptom according to claim 1 Agent, it is characterised in that: every powder charge 0.5g of described synbiotic compound preparation, containing 10 kinds of probiotics at least total 1010CFU viable bacteria With 9 kinds of total 0.05g of prebiotics；The number of active bifid bacteria in probiotics: living preparation of lactobacillus number: streptococcus viable count ratio is 2:2: 1；Every kind of the number of active bifid bacteria is equal；Every kind of living preparation of lactobacillus number is equal.
8. a kind of synbiotic for helping to alleviate no solid lesion hypertension symptom as described in claim 1-7 any one The preparation method of compound preparation, it is characterised in that: the preparation method the following steps are included:
S1: quantitatively weighing, and all raw materials are weighed according to above-mentioned component；
S2: probiotic's culture, by bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, lactobacillus bulgaricus and streptococcus thermophilus are respectively put into ten Further expansion culture is carried out in culture dish；
S3: probiotics fermention is supported, and is being fermented, will fermented respectively to above-mentioned 10 kinds of probiotics using food-grade microorganisms fermentation condition Liquid is filtered using 0.22 micron membrane filter, obtains wet thallus；
S4: degreasing goat milk is resuspended, to wet thallus obtained by step 3 inside degreasing goat milk is added, it is resuspended, and using cold Freeze the dry acquisition freeze-dried vaccine powder of seasoning, is saved at -20 degrees Celsius；
S5: identification is quantitative again, and the probiotic powder after fermentation is used technology plate assay viable bacteria density, is walked for S6-1 or S6-2 Suddenly；
S6-1: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio and are made capsule by mixing glue capsule, Capsule uses enteric solubility outer wall, and protection synbiotic completely passes through stomach, into enteron aisle, guarantees probiotics viability, and -20 ~ 4 Degree Celsius storage cold chain transportation and sale；
S6-2: 10 kinds of Freeze-dry Powder of Probioctics and 9 kinds of prebiotics are mixed in a certain ratio, degreasing are added by mixing solid beverage processed Solid beverage is made in goat milk powder and other auxiliary materials, and in -20 ~ 4 degrees Celsius of storage cold chain transportations and sale.
CN201811181446.3A 2018-10-11 2018-10-11 A kind of synbiotic compound preparation and preparation method thereof for helping to alleviate no solid lesion hypertension symptom Pending CN109432333A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811181446.3A CN109432333A (en) 2018-10-11 2018-10-11 A kind of synbiotic compound preparation and preparation method thereof for helping to alleviate no solid lesion hypertension symptom

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811181446.3A CN109432333A (en) 2018-10-11 2018-10-11 A kind of synbiotic compound preparation and preparation method thereof for helping to alleviate no solid lesion hypertension symptom

Publications (1)

Publication Number Publication Date
CN109432333A true CN109432333A (en) 2019-03-08

Family

ID=65545142

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811181446.3A Pending CN109432333A (en) 2018-10-11 2018-10-11 A kind of synbiotic compound preparation and preparation method thereof for helping to alleviate no solid lesion hypertension symptom

Country Status (1)

Country Link
CN (1) CN109432333A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110279118A (en) * 2019-06-14 2019-09-27 浙江大学宁波理工学院 A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method
CN112841506A (en) * 2021-02-03 2021-05-28 广州悦芯科技有限公司 Functional convenient food containing probiotics for reducing blood fat and preparation method thereof
CN114403231A (en) * 2021-09-06 2022-04-29 盐城工学院 Active probiotic solid beverage and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104000189A (en) * 2013-12-09 2014-08-27 胡安然 Food for curing hypertension
CN106820156A (en) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 A kind of probiotic composition of regulating intestinal canal flora health
CN107518073A (en) * 2017-08-10 2017-12-29 山东阳春羊奶乳业有限公司 A kind of probiotics goat milk piece and preparation method thereof
CN108467846A (en) * 2018-07-04 2018-08-31 中科宜康（北京）生物科技有限公司 The cultural method of lactobacillus acidophilus and its application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104000189A (en) * 2013-12-09 2014-08-27 胡安然 Food for curing hypertension
CN106820156A (en) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 A kind of probiotic composition of regulating intestinal canal flora health
CN107518073A (en) * 2017-08-10 2017-12-29 山东阳春羊奶乳业有限公司 A kind of probiotics goat milk piece and preparation method thereof
CN108467846A (en) * 2018-07-04 2018-08-31 中科宜康（北京）生物科技有限公司 The cultural method of lactobacillus acidophilus and its application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吴克刚等: "《食品微胶囊技术》", 31 July 2006, 中国轻工业出版社 *
张大禄: "《科学解读保健食品：选对吃好保健康》", 31 January 2016, 中国医药科技出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110279118A (en) * 2019-06-14 2019-09-27 浙江大学宁波理工学院 A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method
CN112841506A (en) * 2021-02-03 2021-05-28 广州悦芯科技有限公司 Functional convenient food containing probiotics for reducing blood fat and preparation method thereof
CN114403231A (en) * 2021-09-06 2022-04-29 盐城工学院 Active probiotic solid beverage and preparation method thereof
CN114403231B (en) * 2021-09-06 2024-06-25 盐城工学院 Active probiotic solid beverage and preparation method thereof

Similar Documents

Publication Publication Date Title
US20100166721A1 (en) Probotic compositions and uses thereof
US20110165127A1 (en) Dairy-derived probiotic compositions and uses thereof
Mckinley The nutrition and health benefits of yoghurt
CN105985918B (en) Anti-obesity lactic acid bacteria strain and application thereof in food composition and medical composition
CN104413334A (en) Edible composition as well as preparation method and application thereof
Anzawa et al. Effects of synbiotics containing Bifidobacterium animalis subsp. lactis GCL2505 and inulin on intestinal bifidobacteria: A randomized, placebo‐controlled, crossover study
CN106036911A (en) Probiotics diet composition and functional food for regulating blood glucose level
US20140314719A1 (en) IBS Treatment
CN112056399A (en) Probiotic composition for enhancing immunity and application thereof
US10314867B2 (en) Composition for reducing intestinal gas production
CN106176833A (en) A kind of prevent and treat diabetes the compound probiotic liquid controlling body weight and preparation method thereof
CN109432333A (en) A kind of synbiotic compound preparation and preparation method thereof for helping to alleviate no solid lesion hypertension symptom
CN109481510A (en) It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof
CN108850397A (en) A kind of probiotic gel candy and preparation method thereof of only diarrhea
CN105142654A (en) Lachnospiraceae in the gut microbiota and association with body weight
JP2023544655A (en) Compositions that promote defecation and their uses
CN113142304A (en) Probiotic composition for promoting human body metabolism to generate yellow feces and application thereof
CN112273657A (en) Probiotic composition for preventing or improving allergic diseases, preparation method and application
CN108795823B (en) It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application
EP2575834B1 (en) Probiotic strains for use in improving transepithelial resistance
ES2963547T3 (en) IBS treatment with probiotics
Arora et al. Therapeutic potential of probiotics: A ray of hope or nightmare?
TWI667344B (en) Lactobacillus reuteri strain GMNL-263 and composition thereof capable of improving hypertension
Murphy et al. Probiotics as curators of a healthy gut microbiota: delivering the solution
US20190388484A1 (en) Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190418

Address after: 214135 Room 573, Swan Block D, Wuxi Software Park, 111 Linghu Avenue, Xinwu District, Wuxi City, Jiangsu Province

Applicant after: Jiangsu Hongzhong Baide Biotechnology Co., Ltd.

Address before: 214135 5th Floor, Southeast Courtyard, 99 Linghu Avenue, New District, Wuxi City, Jiangsu Province

Applicant before: Zhang Junyi

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190308